TP53 and cancer: In line with our findings, Hong et al. recently reported that somatic aberrations of TP53 and multiple negative regulators including TRAF3, CYLD and NFKBIA were commonly detected in pulmonary LELC, suggesting their important roles in this unique cancer type [10].